Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age

Li Min Huang, Chin Yun Lee*, Tzou Yien Lin, Jong Min Chen, Ping Ing Lee, Ching Ying Hsu

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

15 Scopus citations


A second generation acellular pertussis vaccine (component pertussis vaccine) containing purified pertussis toxin (PT) and filamentous haemagglutinin (FHA) was tested for its immunogenicity and safety in 2-month-old infants in comparison with first-generation acellular and whole-cell pertussis vaccines. At the ages of 2, 4, 6, and 18 months, respectively, 350 subjects were inoculated one dose of pertussis vaccine, which was combined with diphtheria and tetanus toxoids. Both acellular and component vaccines elicited significantly much fewer local and systemic reactions than whole-cell vaccine did. Besides, although not reaching statistical significance, the component vaccine was less reactogenic than the acellular vaccine. After each dose of the primary immunization, antibodies against PT and FHA were much higher in acellular and component pertussis vaccinees than in whole-cell vaccinees. However, at 18 months of age, just before the booster dose, both anti-PT and anti-FHA declined very close to, or even lower than, the prevaccination levels in all three groups and then responded rapidly to a booster dose to attain high levels. The booster responses were also significantly higher (P < 0.01)) in acellular and component groups than in whole-cell group. Component and acellular vaccines induced similar levels of anti-FHA but the former induced higher anti-PT than the latter (P < 0.01). Our results indicate that both in primary immunization and as a booster, acellular and component pertussis vaccines are much more immunogenic for PT and FHA and much less reactogenic than whole-cell vaccine. However, the persistence of anti-PT and anti-FHA was not as good as one can expect from other protein antigens without giving a booster dose. A long-term follow-up of the vaccinees has been underway to understand the persistence of these antibodies after the first booster.

Original languageEnglish
Pages (from-to)916-922
Number of pages7
Issue number9
StatePublished - 06 1996
Externally publishedYes


  • Acellular pertussis vaccine
  • Antibody persistence
  • Component pertussis vaccine
  • Whole-cell pertussis vaccine


Dive into the research topics of 'Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age'. Together they form a unique fingerprint.

Cite this